Wellness Education
Lean Body
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides work by mimicking natural gut hormones to regulate appetite, blood sugar, and fat metabolism.
22%
Average body weight reduction with Tirzepatide
24%
Greater weight loss vs. single-agent therapies
~40%
Reduction in hunger signaling via hypothalamic pathways
How They Work
These peptides bind to receptors in the gut, brain, and pancreas to reduce hunger signals, slow gastric emptying, stimulate insulin release, and promote fat breakdown. Triple agonists like Retatrutide additionally activate glucagon receptors to further increase daily caloric burn and support lean mass preservation.
Key Benefits
Appetite Control
Reduces hunger signals by up to 40% through hypothalamic pathways
Fat Loss
Clinical trials show 15-22% total body weight reduction
Blood Sugar
Improves insulin sensitivity and fasting glucose
Cardiovascular
Emerging data shows reduction in heart attacks and stroke risk
Lean Body Category
7 compounds in this category
Browse all compounds →Educational Content. Category content is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Compounds in Lean Body
7 compoundsTirzepatide
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgRetatrutide
Triple GLP-1/GIP/Glucagon Agonist
- Broadest receptor pathway activation — 3 mechanisms at once
- Enhances daily energy expenditure and lean mass preservation
Reference Codes
[RT20]20mg[RT30]30mgSemaglutide
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgAOD-9604
HGH Fragment 177-191
- Isolates the fat-loss mechanism of growth hormone without systemic side effects
- Granted GRAS status by the FDA in 2007 for oral anti-obesity applications
Reference Codes
[5AD]5mgCagrilintide
Long-Acting Amylin Analogue
- Amylin-pathway satiety — complementary to GLP-1 receptor agonists
- Long-acting acylated design supports convenient once-weekly dosing
Reference Codes
[CGL5]5mg[CGL10]10mgCagriSema
Amylin + GLP-1 Dual Agonist
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Reference Codes
[CS10]10mg (Cagri 5mg + Sema 5mg)5-Amino-1MQ
NNMT Inhibitor for Fat Metabolism
- Entirely distinct from GLP-1 and amylin pathways — a new axis for metabolic support
- Targets fat storage at the enzymatic level rather than appetite signaling
Reference Codes
[5AM]5mg[50AM]50mgResearch in Lean Body
CagriSema: REDEFINE Data, the REIMAGINE 2 T2D Win, and Where the Compound Lands
CagriSema combines cagrilintide and semaglutide — what REIMAGINE 2 showed in type 2 diabetes, why REDEFINE 4 missed against Zepbound, and where the compound actually stands.
April 6, 2026 · 14 min read
Semaglutide: STEP Trials, SELECT Cardiovascular Outcomes, and the Compounding Landscape
The semaglutide research picture — STEP trial weight loss data, SELECT cardiovascular outcomes, side effects, muscle loss, and what happened to the compounding landscape.
April 4, 2026 · 16 min read
5-Amino-1MQ: A Completely Different Approach to Fat Metabolism
How inhibiting the NNMT enzyme shifts fat cells from storage mode to energy expenditure — without suppressing appetite or requiring injection.
March 27, 2026 · 11 min read
AOD-9604: The HGH Fragment Approach to Fat Loss
AOD-9604 mimics the fat-burning fragment of growth hormone without the side effects — what the Australian trials showed and how it compares to GLP-1 agonists.
March 19, 2026 · 11 min read
GLP-1 Peptides: The Complete Class Guide
The GLP-1 peptide class explained — how incretins work, what defines the class today, and how semaglutide, tirzepatide, retatrutide, and CagriSema compare.
March 14, 2026 · 14 min read
Retatrutide vs Tirzepatide: How the Triple Agonist Compares to the Current Standard
Retatrutide adds glucagon receptor activation to the GLP-1/GIP base — how the triple agonist Phase 2 data compares to tirzepatide and what Phase 3 needs to confirm.
February 7, 2026 · 15 min read
Tirzepatide vs Semaglutide: The SURMOUNT-5 Head-to-Head and What It Settled
The first head-to-head trial of tirzepatide vs semaglutide — SURMOUNT-5 data (NEJM 2025), Mounjaro vs Zepbound, the GIP receptor debate, and side effects compared.
February 3, 2026 · 16 min read
All compound profiles are for educational reference only. This content does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider.